SCHEMBL4374428

SCHEMBL4374428

CC(C(=O)O)c1cccc(C(C)(O)c2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 7/20 0.55
PTGS2 P35354 6/20 0.55
MAPT P10636 3/20 0.55
CXCR1 P25024 2/20 0.55
CXCR2 P25025 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 2/20 0.55
HPGD P15428 2/20 0.55
SLC22A6 Q4U2R8 2/20 0.55
HIF1A Q16665 2/20 0.55
RECQL P46063 1/20 0.55
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP3A4 P08684 1/20 0.55
MAPK1 P28482 1/20 0.55
PMP22 Q01453 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CXCL8 P10145 1/20 0.55
THPO P40225 1/20 0.55
AKR1C3 P42330 6/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12129513 1.00 PTGS1 (0.55) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL3145951 0.87 PTGS1 (0.54) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL7357616 0.85 PTGS1 (0.56) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL4386602 0.81 MME (0.47) CYP3A4CYP1A2CYP2C9CYP2C19
SCHEMBL1993610 0.80 AKR1C3 (0.66) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL1760202 0.80 AKR1C3 (0.66) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL4943386 0.79 PTGS2 (0.50) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL602096 0.78 PTGS2 (0.69) PTGS1PTGS2MAPTCXCR1CXCR2
SCHEMBL11432364 0.76 KMT2A (0.46) MAPTHIF1AALDH1A1CYP3A4MAPK1
SCHEMBL11858017 0.75 ALDH1A1 (0.44) LMNAHIF1AKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493402-B2 Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells DOMPÉ FARMACEUTICI S.P.A. (IT) 2016-11-15 US disclosed
US-20130079514-A1 \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ Dompé S.p.A. (IT) 2013-03-28 US disclosed
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 EP disclosed
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-16 US disclosed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 EP disclosed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils CXCL8, MMP8, CCR8 PTGS1 171/4885PTGS2 219/4885MAPT 3584/4885
US-20130079514-A1 \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ C5AR2, C3AR1, C5AR1 PTGS1 565/4885PTGS2 333/4885MAPT 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.